S&P 500
7,357.80
-0.44%
Dow Jones
51,945.60
-0.47%
Nasdaq 100
29,082.80
-1.56%
Russell 2000
3,005.17
-0.36%
FTSE 100
10,505.10
-0.38%
Nikkei 225
69,696.60
-2.22%
AbCellera Biologics

ABCL Q3 2025 Earnings

Reported Nov 6, 2025 at 4:21 PM ET · SEC Source

Q3 25 EPS

$-0.19

MISS 17.28%

Est. $-0.16

Q3 25 Revenue

$9.0M

BEAT +41.40%

Est. $6.3M

vs S&P Since Q3 25

+57.9%

BEATING MARKET

ABCL +66.6% vs S&P +8.6%

Market Reaction

Did ABCL Beat Earnings? Q3 2025 Results

AbCellera Biologics delivered a mixed third quarter, posting revenue of $8.96 million that cleared the $6.33 million consensus by 41.40% and grew 37.6% year over year, while its loss per share of $0.19 came in wider than the $0.16 analysts had expect… Read more AbCellera Biologics delivered a mixed third quarter, posting revenue of $8.96 million that cleared the $6.33 million consensus by 41.40% and grew 37.6% year over year, while its loss per share of $0.19 came in wider than the $0.16 analysts had expected, missing by 17.28%. The earnings shortfall traces directly to a sharp acceleration in R&D spending, which climbed to $55.03 million from $40.97 million a year ago as the company channeled resources into its internal pipeline, including $15.00 million directed to two proprietary programs in the quarter alone. Despite the deeper net loss of $57.12 million, the operating loss narrowed to $76.28 million from $93.66 million, aided by a dramatic drop in depreciation and impairment charges as platform investments near completion. With lead candidates ABCL635 and ABCL575 advancing through Phase 1 trials and roughly $680 million in available liquidity, AbCellera is positioning its substantially completed platform as the foundation for a broadening clinical pipeline, including newly nominated development candidate ABCL688.

Key Takeaways

  • • Research fees revenue grew to $8.8 million from $6.3 million year-over-year
  • • Greater proportion of R&D expenses directed toward internal programs, including $15 million on two internal programs in Q3
  • • Depreciation, amortization, and impairment charges decreased significantly to $5.2 million from $36.9 million year-over-year
24/7 Wall St

ABCL YoY Financials

Q3 2025 vs Q3 2024, source: SEC Filings

24/7 Wall St

ABCL Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q1 26

“AbCellera successfully delivered on two corporate priorities this quarter by starting activities at our new clinical manufacturing facility and substantially completing our platform investments.”

— Carl Hansen, Q3 2025 Earnings Press Release

Back to ABCL Stock Page